Donald C. Freeman, Jr., PhD, was President/CEO of HydroCision, Inc., a fluidjet-based medical device company, from 1996 to 2002, when he retired. From 1996 until 2000, he was also Chairman, CEO and a Director of RadioMed Corporation, developer of medical devices incorporating radioisotopes for inhibition of cellular proliferation. RadioMed was acquired by IBA in 2000. Prior to 1996, Dr. Freeman was a Principal of Grayson & Associates, an investment banking firm specializing in the healthcare field. Previously, he was President/CEO of Intra-Sonix, Inc and Xenotech Laboratories, both medical device companies. Still earlier, he was President of Davol, Inc, which was acquired by C. R. Bard, after which he served as a Group Vice President of Bard. Before Davol, he was President of Friesen International, a hospital design firm owned by American Medical International. He was Director, New Business Development for Union Carbide Corporation, where he was also General Manager of its clinical diagnostics, radiopharmaceuticals and imaging businesses. Dr. Freeman’s early career was as a scientist at Union Carbide. He holds an ScB Degree from Brown and a PhD in chemistry from the University of Maryland, and did post-doctoral research in physics at Duke. He is inventor or co-inventor on 22 US patents, plus foreign counterparts. He attended the Harvard Business School Advanced Management Program and has been a Director of numerous companies, public and private, in the healthcare field. He is currently on the board of directors of Medical Record Bank, Inc., Design Mentor, Inc., Respiratory Motion, Inc., Theratorr, Inc., and Pluromed Corporation (until recently acquired). He holds equity in those companies, and is also currently invested in 5 other early-stage ventures. Dr. Freeman is also a mentor in the MassMedic IGNITE program and a board member and advisor at the North Shore InnoVentures Business Incubator.